Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
about
Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapyCrizotinib: A comprehensive reviewClinical use of crizotinib for the treatment of non-small cell lung cancerCrizotinib resistance: implications for therapeutic strategiesCrizotinib: from discovery to accelerated development to front-line treatmentTargeted therapies and immunotherapy in non-small-cell lung cancerTackling ALK in non-small cell lung cancer: the role of novel inhibitorsNon-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCMolecular Subtypes and Personalized Therapy in Metastatic Colorectal CancerOncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesALK inhibitors in non-small cell lung cancer: the latest evidence and developmentsALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistanceTaking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease ResearchCrizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancerAdvances in Diagnosis and Treatment of Multiple Primary Lung CancerProgress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancerNovel targeted agents for the treatment of lung cancer in ChinaThe Evolution of Therapies in Non-Small Cell Lung CancerTreating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyOvercoming resistance to targeted therapies in NSCLC: current approaches and clinical applicationALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment optionsMET inhibitors in combination with other therapies in non-small cell lung cancerThe Utilization of Cytologic Fine-Needle Aspirates of Lung Cancer for Molecular Diagnostic TestingCombating acquired resistance to tyrosine kinase inhibitors in lung cancerSystemic and targeted therapies for early-stage lung cancerNon-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial DesignPredictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC)Targeted therapies in development for non-small cell lung cancerAcquired Resistance to Crizotinib from a Mutation in CD74 – ROS1Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategySafety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.Ceritinib in ALK-rearranged non-small-cell lung cancer.Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibCrizotinib in ROS1-rearranged non-small-cell lung cancer.Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
P2860
Q24609974-8479EE6E-39E1-4B42-9852-1E7147849C74Q24624083-1DCBC810-6A3F-47F3-ACE6-E700CC0693BDQ24630466-A64E04C5-2F16-43B6-891D-4746D6CA999DQ26738381-62AFCFE9-34B4-4BDA-A733-4070658EC745Q26738385-DF81BA42-5226-40EA-8FFF-200F4047F14EQ26738986-0FFA98DB-520D-4B8B-BA48-3308C5AD8A56Q26740329-87883B03-13E3-4CAC-B5BF-86FC61BB6F6BQ26741814-0E566C9D-4013-491D-A329-1D71BE45AD2DQ26745427-A601B1D0-43B7-4CA8-A8F3-2188AD9C6039Q26747276-FF0BE9CE-902B-4F30-9208-976CA8B9BB77Q26747329-ED8091B7-EED3-4158-B885-6E770BD0C1D5Q26768158-0AB98A6E-C270-4CA0-BEC8-4648F1DB1DFFQ26769879-966E08D8-D3B7-4F4E-A044-F134EF10D075Q26775347-F2997839-1DAF-4039-AF84-345374858E24Q26775808-46B6F7E5-820F-41DD-A726-F0940A251AFFQ26778500-2F9A1579-35D6-4083-9A92-8017409FF2CCQ26781686-77156CB0-651E-4AEA-AEDE-EABC36D51AB6Q26784298-95C7E547-D1D4-4248-BDBC-6FB677CA9B2CQ26786580-E60D2A41-FB5F-489F-B2B6-E0759FBB50CEQ26786932-25670DE7-7982-4E3E-AD6E-6A0B7527E71BQ26795555-8D393150-EC11-49EE-8310-86E38F20FAAEQ26795556-E236F934-772D-4790-9967-4B99E909F3E0Q26820845-5A35BED9-8F41-450A-8E11-F51C9E55E4C0Q26823203-B7F8943D-3D95-4914-9841-17BAD8D599E9Q26824315-4D55A50C-6C21-46AD-B823-F90459AF878DQ26824877-0ADEF93A-D80F-4BBC-986A-0304B21486CAQ26865490-2914095D-AA3B-4293-970A-76D5FE8866A5Q27003440-104EAB0E-D708-4F8B-AA9F-AA5CEAC0C9F9Q27009492-123F3CD7-4FB7-442B-ADE1-7FC56B388271Q27022852-7019B23C-3E70-451E-930C-462C83DD2315Q27678436-F9BB8A98-1D04-4078-9349-FBE1BC19523DQ27682798-E1B6475C-A463-4F1D-850F-57A2728AA22FQ27852211-4E3B0CA8-2D11-4165-B36D-1DF3B3576A0FQ27852699-D79E1472-A615-42A0-8A84-335D4F904056Q27852806-4987F565-7465-4A15-8513-E07D03FA4979Q27852989-B3070E80-0125-434A-B6CF-27B734C75818Q27853072-241D2390-4314-45B2-A890-C675D430D1A5Q27853075-73F01278-EDE3-4108-8EBF-813DDD600423Q27853360-3846FBAC-7C3D-41F6-BFA8-FFE5E4A5CBAFQ28071903-98DEC333-4E32-4929-B5DD-326662ADEAB2
P2860
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 September 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Activity and safety of crizoti ...... results from a phase 1 study.
@en
Activity and safety of crizoti ...... results from a phase 1 study.
@nl
type
label
Activity and safety of crizoti ...... results from a phase 1 study.
@en
Activity and safety of crizoti ...... results from a phase 1 study.
@nl
prefLabel
Activity and safety of crizoti ...... results from a phase 1 study.
@en
Activity and safety of crizoti ...... results from a phase 1 study.
@nl
P2093
P2860
P50
P1433
P1476
Activity and safety of crizoti ...... results from a phase 1 study.
@en
P2093
A John Iafrate
Alice T Shaw
Benjamin Solomon
D Ross Camidge
Dong-Wan Kim
Eunice L Kwak
Geoffrey I Shapiro
Gregory J Riely
Jeffrey A Engelman
Jeffrey W Clark
P2860
P304
P356
10.1016/S1470-2045(12)70344-3
P577
2012-09-04T00:00:00Z